



EUROGIN 2015

HPV Infection and Related Cancers: Translating Research Innovations into Improved Practice

Sevilla, Spain
February 4-7, 2015
Final Program

Wednesday, Feb. 4

Main Training Course (MTC)

The main training course is designed to provide summaries of the most relevant knowledge on HPV infection and associated diseases with the aim of assisting physicians and educators. The topics covered range from the basic science fundamentals to emerging issues and the clinical uses of screening technologies, prophylactic HPV vaccines and extending to HPV-related diseases in external genitalia and head & neck.

Speakers will present only accepted evidence-based scientific information that has been published in the peer-reviewed medical literature.

9:00 -	MTC1 - From infection to diseases at different anatomic sites	Main Auditorium			
10:30	Chairs : S. Franceschi				
	• HPV related cancers: the comparative figures	Franceschi	S.	France	20
	• Epidemiology, transmission & natural history	Lu	B.	USA	20
	• The biology of HPV infection at different epithelial sites	Doorbar	J.	UK	20
	• HPV immunology: an update	Wu	TC	USA	20
	• Discussion				10

11:00 -	MTC 2 - New strategies & innovations in cervical cancer control	Main Auditorium			
12:45	Chairs : X. Bosch				
	• New standards for HPV-based cervical cancer screening	Franco	E.	Canada	20
	• HPV prophylactic vaccines: lessons learned from 10 years experiences	Brotherton	J.	Australia	20
	• Integrating primary & secondary prevention: new strategies for cervical cancer control LIC vs HIC	Gravitt	P.	USA	20
	• Challenges facing novel HPV multivalent vaccine	Joura	E.	Austria	20
	• The expectancy of HPV therapeutic vaccine	Stanley	M.	UK	20
	• Discussion				5

9:00 - 10:30	OC 1 - HPV testing 1	Auditorium 3			
	Chairs : C. Clavel - M. Einstein				
	• Detection of cervical disease with the Aptima HPV and cobas 4800 HPV assays using SurePath liquid cytology specimens	Chernesky	M.	Canada	7,5
	• Direct genotyping from the Aptima® HPV assay using Anyplex™ II HPV28	Lillsunde Larsson	G.	Sweden	7,5
	• Comparison of HC2 and cobas RealTime PCR in routine HPV testing	Ikenberg	H.	Germany	7,5
	• Definitive separation of high grade from low grade dysplasia using the combined morphological and molecular biomarkers of OncoTect 3Dx	Chargin	A.	USA	7,5
	• A novel, simple and specific test for HPV-induced neoplasia via direct detection of E6 oncoprotein	Schweizer	J.	USA	7,5
	• Performance of the trovagene urine HPV assay in a referral population	Cuzick	J.	UK	7,5
	• Automated versus manual pre-processing of SurePath liquid-based cytology specimens: assessing impact on the performance of the RealTime high risk HPV assay	Sargent	A.	UK	7,5
	• Introduction of Cepheid® HPV tests into cervical screening in Malawi	Cubie	H.	UK	7,5
	• GynTect® a triage test for high-risk human papillomavirus DNA-positive women, may have prognostic potential	Schmitz	M.	Germany	7,5
	• Validation of Novaprep HQ+ liquid-based cytology media for HR HPV detection by Hybrid Capture 2 (HC2)	Prétet	J.L.	France	7,5
	• Validation of two methods of collecting information on HPV test: electronic clinical history and manual register on cervical cancer screening in Spain.	Rodriguez-Sales	V.	Spain	7,5
	• High-risk HPV mRNA in relation to future high-grade lesions among HPV-DNA positive women with minor cytological abnormalities	Forslund	O.	Sweden	7,5

11:00 - 12:45	OC 2 - Epidemiology & natural history 1	Auditorium 3			
	Chairs : I Baussano - G. Ogilvie				
	• Monitoring the impact of the HPV vaccination program and cervical cancer control in Bhutan	Baussano	I.	France	9,5
	• Possible hand-genital HPV infection transmission among heterosexual couples: results from the HITCH study	Louvanto	K.	Canada	9,5
	• Availability of type-specific data on HPV infection in Europe for healthy women and women with cervical, vulvar or vaginal disease	Weiss	T.	USA	9,5
	• Correlation of viral load and persistence for HPV16 and HPV18 in a Dutch cohort of young women	Rog	P.	Netherlands	9,5
	• Serial type-specific human papillomavirus load predicts histological outcome	Verhelst	S.	Belgium	9,5
	• The effect of male circumcision on genital HPV infection and external genital lesions in the HIM study	Albero	G.	Spain	9,5
	• What can twin studies tell us about the aetiology of cervical cancer?	Garland	S.	Australia	9,5
	• 48 month incident HPV infection rates for women HPV negative at baseline: the HPV focal trial	Ogilvie	G.	Canada	9,5
	• Trends of hospital diagnostic demand of papillomavirus. 1996-2013	Ortiz de Lejarazu	R.	Spain	9,5
	• Epidemiology of HPV 6, 11, 16, 18 antibodies among adults in the United States across six years: NHANES 2005-2010	Velasco-Mondragon	H.	USA	9,5
	• Abundance of putatively novel HPV types identified in eyebrows using novel CODEHOP primers and a single tube nested 'hanging droplet' PCR	Kocjan	B.	Slovenia	9,5

14:30 - 16:00	MTC 3 - Management of HPV cervical diseases - the state of the art	Main Auditorium			
	Chairs : W. Kinney				
	• The risk-based management	Stoler	M.	USA	20
	• Triage options of HPV+ women	Meijer	C.	Netherlands	20
	• Triage strategies of abnormal cytology	Kinney	W.	USA	20
	• Post-treatment surveillance options	Arbyn	M.	Belgium	20
	• Discussion				10

16:30 -	MTC 4 - HPV-associated diseases in non-cervical sites - what the clinician should know	Main Auditorium			
18:00	Chairs : A. Giuliano - M. Gillison				
	• Comparative epidemiology and HPV transmission by gender	Giuliano	A.	USA	17
	• Current developments on HPV-caused oropharyngeal cancer	Gillison	M.	USA	17
	• Clinical issues related to anal HPV infection and cancer	Fairley	C.	Australia	17
	• HPV-associated OPC cancer, the state of the art	Brakenhoff	R.	Netherlands	17
	• The potential of HPV prophylactic & therapeutic vaccines	Brisson	M.	Canada	17
	• Discussion				5

14:15 -	OC 3 - Vaccine 1 (Impact)	Auditorium 3			
16:00	Chairs : K. Sundström - K. Soldan				
	• Significant reduction in the incidence of genital warts in young women and men 5 years into the Danish national HPV vaccination program	Baldur-Felskov	B.	Denmark	11
	• Effectiveness of quadrivalent HPV vaccine on genital warts in a real-life setting in Belgium	Dominiak-Felden	G.	France	11
	• Effect of timing of second dose of quadrivalent HPV-vaccine on condyloma incidence	Lamb	F.	Sweden	11
	• Quadrivalent HPV-vaccine effectiveness against cervical lesions: population-based study	Sundström	K.	Sweden	11
	• HPV vaccination in young women at 25 years in Italy. Efficacy, immunogenity and impact on screening for cervical cancer	Carozzi	F.	Italy	11
	• Monitoring the impact of the HPV vaccination program in Rwanda	Clifford	G.	France	11
	• Effect of catch up vaccination on HPV prevalence in routine cervical screening	Baxter	G.	UK	11
	• Projecting the potential public health impact of a universal vaccination programme with a nine-valent HPV vaccine in the United Kingdom	Nikoglou	T.	France	11
	• Characteristics of a cluster-randomized, phase IV HPV vaccination effectiveness trial	Lehtinen	M.	Finland	11

16:30 -	OC 4 - Vaccine 2 (Effectiveness & safety)	Auditorium 3			
18:30	Chairs : M. Lehtinen - K. Canfell				
	• Evidence of cross protection following use of bivalent HPV vaccine in the national HPV immunisation programme in England	Meshner	D.	UK	12
	• Two or three doses for primary HPV vaccination schedules? Systematic review and meta-analysis	Low	N.	Switzerland	12
	• Effectiveness of 3 versus 2 doses of quadrivalent HPV-vaccine on incidence of cervical lesions in a 3-dose vaccination schedule: a population-based study in Denmark and Sweden	Kjaer	S.	Denmark	12
	• Memory B cell responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 year old girls receiving Cervarix® or Gardasil® vaccine	Godi	A.	UK	12
	• Cell-mediated immune response after HPV vaccination	Gonçalves	A.	Brazil	12
	• The effect of herd immunity in different human papillomavirus vaccination strategies: an economic evaluation of the best II study	Haeussler	K.	Italy	12
	• Comparison of safety statements from national authorities and international health bodies for HPV vaccine	Konno	R.	Japan	12
	• The impact of natural immunity on the effectiveness of HPV vaccination	Matthijsse	S.	Netherlands	12
	• Long-term effectiveness of Gardasil™ among adult women in Colombia	Das	R.	USA	12
	• A phase II study of Gardasil in human papillomavirus research: the mid-adult male vaccine study-the MAM study	Giuliano	A.	USA	12

WACC Forum & health education

Benefits and limitations of increasingly informed patients

Sharing knowledge and education for cervical cancer prevention

The WACC Forum (February 4) is organized by the Women Against Cervical Cancer (WACC) Network which represents more than 50 associations from many different countries working for the benefit of women's health and involved in cervical cancer prevention.

This conference gathers players in the public health education sector from a number of countries, to share experiences on effective communication and learning tools aimed to increase HPV disease awareness and patient education towards active prevention.

10:00 - 13:00	WACC 1 - Anti-vaccine movements: tactics and solutions	Madrid			
	Chairs : M. Steben				
	Lecture: The science facts about adverse events & HPV vaccines	Garland	S.	Australia	20
	• Understanding the tricks and tropes of the antivaccinologists	Steben	M.	Canada	15
	• Crisis management: do we need to answer all attacks of antivaccinologists?	Bravo	E.	Spain	15
	• Are all experts banned from sharing their knowledge because of collaboration with the industry?	Meijer	C.	Netherlands	15
	• Composition of expert teams involved in health technology assessment and decision-making in the field of cervical cancer prevention and potential conflict of interest - the example of Belgium	Arbyn	M.	Belgium	12
	• Research on attitudes and acceptance of HPV vaccine	Waller	J.	UK	12
	• Helping community groups in their communication activities	Smith	J.	USA	12
	• Questions and comments from the audience				10

14:30 - 16:00	WACC 2 - Patient survivors' voices: what they want	Madrid			
	Chairs : J. Smith				
	• Information : transmission, risk of cancer, protection				
	- Cervical cancer	Gravitt	P.	USA	10
	- Anal cancer	Bower	M.	UK	10
	- Oropharyngeal cancer	Fakhry	C.	USA	10
	• The interface between science and policy for global cervical cancer control?	Qiao	YL	China	11,5
	• Print media coverage of the link between HPV and oral cancer in the UK	Waller	J.	UK	11,5
	• Current knowledge about the diseases and best standard of care	Smith	J.	USA	10
	• End with the disparity	Ogilvie	G.	Canada	11,5

	• HPV vaccination in Europe: multidisciplinary approach: gynecologists, pediatricians, GP's, Public Health providers	Martinon-Torres	F.	Spain	11,5
	• Discussion				4

16:30 - 18:30	OC 5 - WACC				
	Chairs : F. Martinon-Torres - M. Pitts - J. Waller	Madrid			
	• Understanding cervical screening non-attendance among ethnic minority women	Marlow	L.	UK	8
	• Barriers to and facilitators of compliance with clinical based cervical cancer screening	Östensson	E.	Sweden	8
	• Small scale screening - working beside communities to create a sustainable solution to cervical cancer screening in the Peruvian Amazon	Shannon	G.	Peru	8
	• Acceptance and satisfaction of cervical cancer screening program using visual inspection with acetic acid among women in Morocco	Selmouni	F.	Morocco	8
	• Awareness of human papillomavirus before and after introduction of HPV vaccination: a large population-based survey of Scandinavian women	Thomsen	L.	Denmark	8
	• Knowledge and beliefs about HPV in a vaccinated cohort of young men and women	Pitts	M.	Australia	8
	• Web-based survey on knowledge for cervical cancer prevention among young women: comparison in Japan and Australia	Miyagi	E.	Japan	8
	• Knowledge and prevalence of HPV diseases in Latvia	Rezeberga	D.	Latvia	8
	• A population based survey of school nurses' attitudes to the implemented HPV vaccination programme in Sweden	Grandahl	M.	Sweden	8
	• Hungarian high school students' attitude toward the HPV vaccine	Balla	B.	Hungary	8
	• Primary prevention of HPV infections for adolescents (education and vaccination)	Lepusic	D.	Croatia	8
	• HPV vaccine concerns in Japan - public health and scientific background	Hanley	S.	Japan	8
	• HPV vaccine concerns in Japan - social and political background	Konno	R.	Japan	8
	• Correlates of uptake in school-based routine HPV vaccination: a register-based study of 90,000 girls and their parents	Hansen	B.	Norway	8
	• Acceptability of 2- versus 3-dose HPV vaccination among vaccine providers and mothers of adolescent girls in five countries	Smith	S.	USA	8

EUROGIN 2015 - Jornada Española y Spanish Session

EUROGIN ha convocado su Reunión 2015 en Sevilla, España, a celebrar entre los días 4 y 7 de Febrero de 2015. EUROGIN, como es su norma, ofrece un ámbito académico de conocimiento y discusión de toda la información actualizada sobre el mundo del virus del papiloma humano (VPH). Ahora mismo el reto que afrontamos es llevar a la práctica clínica diaria todas las modificaciones de recomendaciones y conductas sustentadas en la evidencia de alta calidad obtenida en los últimos años: el título de la Reunión de Sevilla así lo anuncia: "*HPV Infection and Related Cancers: Translating Research Innovations into Improved Practice*".

Para cubrir este objetivo todas las últimas novedades van a ser presentadas y debatidas desde una óptica multidisciplinar, aspecto imprescindible para un correcto abordaje de los problemas y sus soluciones. Todas las especialidades concernidas por la patología VPH han sido convocadas, ginecólogos y pediatras, generalistas y epidemiólogos, otorrinolaringólogos y expertos en Salud Pública, virólogos y patólogos. Os esperamos en Sevilla para aprender todos juntos, mejorar nuestra práctica clínica y proteger mejor la salud de nuestra población.

El Programa de la Reunión incluye una Jornada Española y una *Spanish Session*, así como el anuncio de una importante reducción de la cuota de inscripción para los médicos españoles, que contarán también con la posibilidad de inscribirse únicamente a la "Jornada Española".

Wednesday, Feb. 4

Mañana

9:30 - 11:15	JE 1 - Curso de Colposcopia	Auditorium 2			
	Moderador : R. Comino				
	Director: JC Martínez Escoriza				
	• Imágenes Normales	Dexeus	D.		
	• Imágenes Anormales	Coloma	F.		
	• La colposcopia en el contexto de los modelos de cribado actuales	Cararach	M.		
	• Análisis crítico de la Clasificación Colposcópica de Rio de Janeiro 2012	Martínez Escoriza	J.C.		
	• Casos Clínicos	Martínez Escoriza	J.C.		
		Montserrat	J.A.		
11:15 - 13:00	JE 2 - Verrugas Genitales/Cribado/Consenso	Auditorium 2			
	Moderador: R. Comino				
	• Verrugas Genitales: Estudio Multicéntrico Español	de la Fuente	J.		
	• Situación de la Prevención Primaria del Cáncer de Cuello de Útero en España: Fases IV.	Brotons	M.		
	• Presentación del Documento de Consenso de Prevención del Cáncer de Cuello de Útero en España 2014: Consenso SEGO-AEPCC-SEAP-SEC.	Torné	A.		
	• Debate				

Tarde

14:30 - 16:25	JE 3 - Equidad asistencial: de la oncoguía a la practica clínica	Auditorium 2			
	Moderador: J. Ponce				
	• Epidemiología en España de los tumores del Tracto Genital Inferior VPH relacionados	Bruni	L.		
	• Estrategia y metodología del programa OncoGuías SEGO 2008-2016	Cusidó	M.		
	• OncoGuía Prevención Secundaria del Cáncer de Cuello de Útero	del Pino	M.		
	• OncoGuía Cáncer Invasor de Cuello de Útero 2013	Martí	L.		
	• Caso clínico interactivo: Cáncer de Cuello de Útero	Domingo	S.		
	• OncoGuía Cáncer Escamoso Invasor de Vulva 2015	Lombardía	J.		
	• Caso clínico interactivo: Cáncer de Vulva	Alonso Salvador	S.		

17:00 - 18:00	JE 4 - Técnica quirúrgica en el cáncer de cuello uterino	Auditorium 2			
	Moderador: A. Sánchez del Rio				
	• Histerectomía Radical. Anatomía quirúrgica (video)	Muruzábal	J.C.		
	• Linfadenectomía pélvica y ganglio centinela (video)	Gil	A.		
	• Linfadenectomía aorto-cava pre y transperitoneal (video)	Barahona	M.		
	• Efectividad de la robótica en España. Encuesta Nacional ROBOCER 2014	Ponce	J.		

18:00 - 19:00	JE 5 - La educación en el médico de cabecera en el VPH	Auditorium 2			
	Moderadoras: E. Redondo & I. Jimeno				
	En colaboración con SEMERGEN, SEMG				
	• La Educación en VPH del Médico Generalista	Alonso	J.		
	• El papel del Médico Generalista en la Prevención Primaria y Secundaria del Cáncer de Cérvix	Cano	A.		

Thursday, Feb. 5

Main Scientific Sessions include keynote lectures providing a broad overview of the essential issues on cervical cancer prevention by the most prominent experts in their respective field.

8:15 - 9:45	MSS1 - How to introduce HPV testing into primary screening?	Main Auditorium			
	Chairs : J. Dillner - H. Lawson				
	• Do the current criteria for the recommendation of new HPV tests for cervical cancer screening need to be refined?	Iftner	T.	Germany	13
	• Cotesting vs primary standalone HPV testing	Lawson	H.	USA	13
	• What test to use, is genotyping important?	Cuzick	J.	UK	13
	• Ages for HPV screening: when to start, when to stop?	Franco	E.	Canada	13
	• What to do if HPV negative? Interval of screening	Dillner	J.	Sweden	13
	• Impact of vaccination on primary HPV screening	Bosch	X.	Spain	13
	• Discussion				10

9:45 - 11:30	MSS 2 - Surveillance and impact of HPV prophylactic vaccines in population: current picture	Main Auditorium			
	Chairs : J. Brotherton - P.L. Lopalco				
	• Vaccine uptake accross the world	Bloem	P.	Switzerland	12,5
	• Monitoring impact in population	Soldan	K.	UK	12,5
	• Worldwide surveillance of HPV vaccination coverages: the current picture	Bruni	L.	Spain	12,5
	• Changes in disease prevalence in vaccinated women				
	- Genital warts	Arnhem-Dahlström	L.	Sweden	12,5
	- Cervical diseases	Brotherton	J.	Australia	12,5
	• Cancer registries: up to the task of monitoring post vaccination reductions in HPV-related cancers?	Bray	F.	France	12,5
	• Monitoring of RRP in the post vaccine era	Campisi	P.	Canada	12,5
	• Long-term efficacy of HPV vaccination against hard endpoints	Paavonen	J.	Finland	12,5
	• Discussion				5

8:15 - 9:45	OC 6 - Vaccine 3 (New developpments)	Auditorium 3			
	Chairs : P. Bonanni - E. Joura				
	• Long-term effectiveness and safety of Gardasil™ in the Nordic countries	Kjaer	S.	Denmark	10
	• Phase II evaluation of a multivalent HPV L1 virus-like particle (VLP) vaccine	Luxembourg	A.	USA	10
	• Immunogenicity and safety of a novel 9-valent HPV L1 virus-like particle vaccine in boys and girls 9-15 years old; comparison to women 16-26 years old	Olsson	S.	Sweden	10
	• Immunogenicity and safety of a novel 9-valent HPV vaccine in girls 9-15 years of age compared to the quadrivalent vaccine	Olsson	S.	Sweden	10
	• Safety and tolerability of a novel 9-valent HPV virus-like particle vaccine	Moreira	E.	Brazil	10
	• Tolerability and immunogenicity of a multivalent HPV L1 virus-like particle vaccine in 16- to 26-year-old men	Castellsagué	X.	Spain	10
	• End of study efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16-26 year old women	Joura	E.	Austria	10
	• Potential impact of a nine-valent vaccine on human papillomavirus (HPV) related cervical disease in women aged 16-45 years of age, by region	Castellsagué	X.	Spain	10
	• Evaluation of HPV clearance following ProCervix vaccination in HPV 16 / 18 infected women with normal cytology	Bouillette-Marussig	M.	France	10

Clinical Sessions (CS)

The clinical sessions are designed to provide educational strategies and skill-building learning experiences and update of expertise for participants. The clinical sessions should enable participants to integrate in their everyday practice the basic and advanced principles of colposcopy as well as diagnosis and management of cervico-vaginal and vulvar diseases.

8:30 - 10:00	CS 1 - Clinical advances & modern management of vulvar carcinoma	Auditorium 2			
	Chairs : C. Haie-Meder - M. Roy				
	• Current knowledge on burden, epidemiology & carcinogenesis	Tristram	A.	UK	20
	• Human papillomavirus genotype attribution for HPVS 6, 11, 16, 18, 31, 33, 45, 52, 58 in female anogenital cancers.	De Sanjosé	S.	Spain	20
	• The contribution of sentinel lymph node detection & new development in vulvar cancer surgery	van der Zee	A.	Netherlands	30
	• What remains of radiotherapy indications?	Haie-Meder	C.	France	20
	• Discussion				

10:00 - 11:30	CS 2 - HPV infection & precancers of the vulva	Auditorium 2			
	Chairs : A. Fiander - J. Bornstein				
	• Terminology	Bornstein	J.	Israel	13
	• The distribution of 14 HPV types detected in VIN and VaIN lesions from women 15-26 years of age	Garland	S.	Australia	13
	• Epidemiology of HPV infection	Goodman	M.	USA	13
	• Diagnosis	Roy	M.	Canada	13
	• Treatment - Management	Tristram	A.	UK	13
	• Immunotherapy	Van Esch	E.	Netherlands	13
	• Discussion				10

8:30 - 10:00	OC 7 - Head & Neck 1	Madrid			
	Chairs : S. Syrjänen - M. Quer - H. Mirghani				
	• Risk of human papillomavirus-associated head and neck cancer following a diagnosis of cervical intraepithelial neoplasia	Svahn	M.	Denmark	10
	• Human papillomavirus prevalence and genotype profiling in head and neck region: an Italian study	Benevolo	M.	Italy	10
	• The incidence of cervical and head and neck cancer among indigenous people in Australia, Canada, New Zealand, and the United States	Moore	S.	Australia	10
	• Study of HPV and precancerous lesions in the tonsils ("SPLIT"): preliminary results	Combes	J.D.	France	10
	• Prevalence of HPV & P16 ^{INK4A} in multiple primary squamous cell carcinomas of the upper aerodigestive tract	Kulasegarah	J.	Ireland	10
	• Adult onset recurrent respiratory papillomatosis: a retrospective review	Blackwell	N.	UK	10
	• HPV in oral squamous cell carcinoma in India: pathogenesis and clinical implications	Husain	N.	India	10
	• Human papillomavirus detection in oral mucosa can suggest genital infection?	Leal Passos	M.	Brazil	10
	• Molecular identification of HPV and its relationship with the presence of premalignant and malignant lesions of the oral cavity in a general hospital, Arequipa, Peru	Vasquez	A.	Peru	10

10:00 - 11:30	OC 8 - Head & Neck 2	Madrid			
	Chairs : B. Burtneess - L. Licitra				
	• The role of the stroma in Tumour infiltrating lymphocytes (TILs) in oropharyngeal squamous cell carcinoma (OPSCC)	Stern	P.	UK	10
	• Genomic characterization of a novel human Gammapapillomavirus genotype HPV-199 isolated from nazopharynx	Ostrbenk	A.	Slovenia	10
	• HPV concordance between neck metastases and primary tonsillar cancer	Munck-Wikland	E.	Sweden	10
	• Expression of APM components in oropharyngeal carcinomas in relation to human papillomavirus (HPV) and clinical outcome	Ramqvist	T.	Sweden	10
	• Methylation of HPV16 URR SP1 and E2 binding sites 3 and 4 in matched HPV16 positive primary / metastasis OPSCC pairs	Kalteis	M.	Germany	10
	• Meta-analysis on p16 ^{ink4a} accuracy to identify HPV transformation in oropharyngeal squamous cell carcinomas	von Knebel Doeberitz	M.	Germany	10
	• Determination of human papillomavirus significance in oral premalignant lesions in association with clinical parameters and p16 ^{ink4a} immunohistochemistry	Prigge	E.	Germany	10
	• E6/E7 mRNA in situ hybridization is sensitive and specific to predict patient outcomes in oropharyngeal squamous cell carcinoma (SCC)	Zhai	J.	USA	10
	• Comparative analysis of microRNAs in HPV-positive and negative oropharyngeal cancers highlights different oncogenic mechanisms	Mirghani	H.	France	10

The colposcopy course is an intensive course conducted by 2 highly experienced colposcopists/oncologists. They will present the most up-to-date knowledge relating to colposcopy practice as well as of the management of the cervix and lower genital tract precancer. There will be lectures as well as a very informal interactive tutorial which will be clinically oriented. Topics will range from the basic (i.e. normal cervix) to advanced (i.e. micro-invasion and glandular disease). A CD (PDF format) of all PowerPoint lectures will be given out.

8:30 - 12:00	Colposcopy course	Bruselas			
	Chairs : A. Singer - N. Pisal				
7:30	• Registration				
8:00	• The normal cervix				
8:20	• New ideas on CIN and cervical glandular disease and their detection - use of cytology +/- HPV				
9:10	• Discussion				
9:20	• The abnormal cervix - the use of colposcopy (including video presentations)				
10:10	• Discussion				
10:20	• Coffee				
10:30	• Why, who, how to treat CIN/glandular disease				
11:10	• Interactive case presentation				
11:30	• Summary and close				

14:45 - 16:00	MSS 3 - Funding cervical cancer control	Main auditorium			
	Chairs : E. Franco				
	• Being victims of our own success: funding decreases for cervical cancer control	Franco	E.	Canada	16
	• The agenda agencies and charity organizations				
	- NIH	Wiesch	D.	USA	16
	- PATH	LaMontagne	S.	USA	16
	• What do financial cuts in health care systems means for cervical cancer prevention in Europe?	Bosch	X.	Spain	16
	• Discussion				10

16:30 - 18:00	MSS 4 - Methods of triage of HPV+ women	Main auditorium			
	Chairs : C. Meijer, A. Lorincz				
	• Cytology	Dillner	J.	Sweden	16
	• Host methylation	Meijer	C.	Netherlands	16
	• Viral methylation and p16 mRNA test	Lorincz	A.	UK	16
	• p16	Wentzensen	N.	USA	16
	• Combination strategies	Stoler	M.	USA	16
	• Discussion				10

Scientific Session (SS)

The concurrent scientific sessions feature presentations of selected abstracts on new findings covering a broad range of topics related to genital cancer prevention and management of patients with HPV-associated diseases.

14:45 - 16:15	SS 1 - Immunotherapy of HPV-associated diseases	Auditorium 3			
	Chair : M. Stanley - P. Stern				
	• Development of immune checkpoint inhibitors for SCCHN therapy	Melillo	G.	USA	10
	• Optimization and development of a therapeutic anti-HPV vaccine in Ear, Nose, Throat (ENT) cancer	Badoual	C.	France	10
	• HPV-specific immunotherapy (VGX-3100) induces potent T-cells responses and regression of cervical intraepithelial neoplasia in a randomized phase IIB study	Morrow	M.	USA	10
	• Protease inhibitor in treatment of CIN	Hampson	I.	UK	10
	• Generation of chimeric P16INK4A HPV16 L1 particles for second generation HPV vaccines	Faulstich	F.	Germany	10
	• A phase I/IIa trial targeting p16INK4a by peptide vaccination in patients with human papillomavirus-associated cancer	Reuschenbach	M.	Germany	10
	• Human papilloma viral clearance following HPV targeted immunotherapy, tipapkinogen Sovacivec, in patients with high grade cervical intraepithelial neoplasia (CIN)	Harper	D.	USA	10
	• Vaxicelase, a new adenylate cyclase-based vaccine vector for multivalent HPV therapeutic vaccination	Misseri	Y.	France	10
	• Discussion				10

16:40 - 18:00	SS 2 - New challenges facing HPV 16 & 18 infection	Auditorium 3			
	Chair : X. Bosch				
	• HPV 16 & 18 prevalence and burden of associated cancers	Clifford	G.	France	13
	• Assessing cancer risk of HPV 16 & 18 infection	Franco	E.	Canada	13
	• Immune responses, regression and persistence of HPV 16 & 18	Moscicki	AB	USA	13
	• Immune responses to HPV therapeutic vaccines	Wu	TC	USA	13
	• ProCervix, a new vaccine for HPV 16 & 18 infected women prior to development of high-grade cervical lesions: from Phase I to Phase II.	Van Damme	P.	Belgium	13
	• New paradigms of HPV 16 & 18 associated cancer control, the respective role of prevention, screening and immunotherapy	Brisson	M.	Canada	13
	• Discussion				10

14:45 - 16:15	CS 3 - ADC in situ and invasive adenocarcinoma of the cervix: an update	Auditorium 2			
	Chairs : K. Ault				
	• Current worldwide figures	Ault	K.	USA	13
	• Human papillomavirus types in glandular lesions of the cervix: A meta-analysis of published studies	Clifford	G.	France	13
	• Molecular approaches	Doorbar	J.	UK	13
	• Overview of relevant immunological factors for adenocarcinoma of cervix	Stern	P.	UK	13
	• Cervical screening and adenocarcinoma: Impact of cytology based screening and likely impact of HPV testing	Sasieni	P.	UK	13
	• HPV prophylactic vaccine efficacy & impact	Brown	D.	USA	13
	• Discussion				10

16:30 - 18:00	CS 4 - The new face of colposcopy at the age of technical progress	Auditorium 2			
	Chairs : W. Prendiville - P. Hillemanns				
	• Colposcopy e-training	Singer	A.	UK	16
	• Colposcopic performance & utility today	Dexeus	S.	Spain	16
	• Indications of colposcopy based on HPV screening	Huh	W.	USA	16
	• New biometric diagnostic	Prendiville	W.	Ireland	16
	• The use of an objective test for colposcopic trainees: a ten-year experience	Roy	M.	Canada	16
	• Discussion				10

18:00 -	OC 9 - Colposcopy - Management	Auditorium 2			
19:30	Chairs : E. Siegler - K. Elfgrén				
	• Organized primary HPV screening in Sweden. Colposcopic and histopathologic evaluation of HPV++ women aged 56-60	Elfgrén	K.	Sweden	8
	• Spectroscopy in cervical cancer screening	Kirubamani	H.	India	8
	• When should endocervical curettage be done?	Pretorius	R.	USA	8
	• EQE of cervical dysplasia: cytology-biopsy evaluation is mandatory for good patient management	Vanscheeuwijck	C.	Belgium	8
	• HPV triage of low grade abnormalities in immunised women - insights from the SHEVa study	Bhatia	R.	UK	8
	• SperAnZA study: preliminary results of HPV vaccination after loop electrosurgical excision procedure for cervical intraepithelial neoplasia	Ghelardi	A.	Italy	8
	• ECO-ROCS (evaluation of clinical outcome after reduction of conization size), study design	Schwarz	T.	Germany	8
	• Influence of glacial acetic acid on HPV detection - a study of 140 cases of CIN2+	Cuschieri	K.	UK	8
	• Dynamic spectral imaging for post-treatment triage	Founta	C.	UK	8
	• Realtime in vivo microscopic imaging of the cervix using confocal laser endomicroscopy: preliminary observations and feasibility study.	Degueldre	D.	Belgium	8
	• Overtreatment in See-and-Treat management of Cervical Intraepithelial Neoplasia; A Systematic Review and Meta-analysis	Ebisch	R.	Netherlands	8

14:45 -	OC 10 - HPV testing 2	Madrid			
16:00	Chairs : H. Cubie - J.L. Prétet				
	• Technical evaluation of the Xpert® HPV Assay in a General Screening Population - an assessment of the clinical performance	Cuzick	J.	UK	7,5
	• HPV typing for the triage of HPV-positive ASC-US women may reduce costs due to avoidable colposcopies	Parisi	M.	USA	7,5
	• Detection of high-risk Human Papillomavirus E7 Proteins	Koch	I.	Germany	7,5
	• Clinical validation of E1-based "HPV Easy DNA Array" genotyping test developed by AID/GenID	Pesic	A.	Germany	7,5
	• Cross-reactivity to untargeted, low-risk HPV genotypes by cobas, Aptima and HC2	Preisler	S.	Denmark	7,5
	• Human papillomavirus infection caused by HPV types 52 and 58 and its role in the development of cervical intraepithelial neoplasia	Prilepskaya	V.	Russia	7,5
	• Does human genomic DNA cause false positive HPV test results	Dong	J.	USA	7,5
	• Post-conus samples and HPV testing with HC2 and cobas using SurePath: results from two Danish laboratories	Fornari	D.	Denmark	7,5
	• Virtual screening of human papillomavirus oncoprotein E7	Silva	G.	Brazil	7,5

16:30 -	OC 11- Epidemiology & natural history 2	Madrid			
18:00	Chairs : P. Sparen - H. Ikenberg				
	• HPV genotypic distribution in patients with cervical cancer in Thailand	Kantathavorn	N.	Thailand	7,5
	• HLA-G polymorphism and HPV transmission among heterosexual couples in the HITCH study	Louvanto	K.	Canada	7,5
	• Do HPV 16 and 18 predict a higher risk of CIN2+ than other high-risk HPV genotypes in triage?	Tropé	A.	Norway	7,5
	• "Safety in numbers" - HPV genotype-specific vs. pooled high-risk approaches to CIN3+ risk stratification	Vaughan	L.	USA	7,5
	• Use of Oncotect HPV E6/E7 mRNA as a triage test finds more cancer and high grade dysplasia than HPV 16/18 genotyping or dual staining	Karakitsos	P.	Greece	7,5
	• Sexually transmitted infections among HIV positive and HPV high-risk patients in North Tongu district, Ghana - an ACCESSING* pilot trial	Krings	A.	Germany	7,5
	• Persistence of high risk HPV infections among women in the North Tongu district of Ghana - participating in the ACCESSING* trial	Dunyo	P.	Ghana	7,5
	• Prevalence of risk factors associated with HPV and HIV positivity and cervical cancer among Cameroonian women	Catarino	R.	Switzerland	7,5
	• The effect of HIV infection on penile high-risk HPV incidence and clearance among MSM	Van Santen	D.	Netherlands	7,5
	• High-risk types of the human papillomavirus in women diagnosed with a precancerous lesion	Iwaniec	K.	Poland	7,5
	• Epidemiological study of high-risk HPV in Midi-Pyrénées (France) with high-risk HPV RealTime PCR in 2013	Bernier	M.	France	7,5
	• Human papillomavirus and chlamydia trachomatis co-infection and the severity of cervical neoplasia	Rabelo-Santos	S.	Brazil	7,5

Friday, Feb. 6

8:30 - 10:00	MSS 5 - Moving from cyto to HPV-based primary screening - Mutualizing experiences / implementation issues	Auditorium 3			
	Chairs : J. Cuzick - G. Ronco				
	• Status of cervical cancer screening in European countries and guidelines	von Karsa	L.	France	11,5
	• Introduction of primary HPV screening in organized screening programs	Dillner	J.	Sweden	11,5
	• Implementation of HPV screening : national vs regional projects (organization, assessment, problems, solutions, results, communications)				
	- Netherlands	Meijer	C.	Netherlands	10
	- Italy	Ronco	G.	Italy	10
	- Germany	Hillemanns	P.	Germany	10
	- Spain	Granado de la Orden	S.	Spain	10
	- US (FDA approval)	Lawson	H.	USA	10
	• Updated benefits & harms of HPV DNA screening implementation	Anttila	A.	Finland	11,5
	• Discussion				5
10:00 - 11:30	MSS 6 - Roadmap 2015: Management & control of HPV associated diseases - current knowledge and new horizons - a debate	Auditorium 3			
	Chairs : S. Franceschi - J. Monsonego				
TOPIC 1	How HPV knowledge has changed our practice: screening and management of neoplastic lesions				
Section 1	• Cervix				
	- HPV screening				
	• in non-vaccinated women	Wentzensen	N.	USA	5
	• in vaccinated women	Berkhof	H.	Netherlands	5
		Canfell	K.	Australia	5
	- Role of HPV in the management of abnormal Pap & CIN	Einstein	M.	USA	5
		Arbyn	M.	Belgium	5
Section 2	• Anus	Fairley	C.	Australia	5
		Bower	M.	UK	5
Section 3	• Oropharyngeal cancers (OPC)	Pai	S.	USA	5
		Fakhry	C.	USA	5
TOPIC 2	How HPV knowledge has changed our practice: current and future vaccines				
	• State of the art of HPV vaccine	Brotherton	J.	Australia	5
	• Positioning the value of the new HPV vaccine	Jit	M.	UK	5
	• Utility of cervical cancer screening in the era of multivalent and therapeutic vaccines	Gravitt	P.	USA	5
	• Impact of prophylactic HPV vaccine in cancers other than cervical cancer	Brisson	M.	Canada	5
	• Discussion				25

FORUM HEAD & NECK CANCERS

8:15 - 10:00	H&N I - HPV driven oropharyngeal cancers (OPC): the global view	Auditorium 2			
	Chairs : X. Castellsagué - A. Chaturvedi				
	• Burden of HPV H&N cancer a new entity? An emerging epidemic?	Chaturvedi	A.	USA	15,5
	• HPV distribution & epidemiology	Castellsagué	X.	Spain	15,5
	• Risk factors for HPV head and neck cancers	Gillison	M.	USA	15,5
	• Defining risk in HPV-associated head and neck cancer	Burtness	B.	USA	15,5
	• Natural history - carcinogenesis	Roberts	S.	UK	15,5
	• Role of immunity	Pawlita	M.	Germany	15,5
	• Discussion				10

14:45 - 16:30	H&N II - The HPV value for detection, control and management of oropharyngeal cancers (OPC)	Auditorium 2			
	Chairs : C. Fakhry - S. Pai				
	• Are HPV head and neck cancers preventable by screening, early detection & immunization	Fakhry	C.	USA	15,5
	• Diagnosis & detection	Lacau St Guily	J.	France	15,5
	• Biomarkers in HPV+ tumors	Pawlita	M.	Germany	15,5
	• The role of HPV status in the treatment option of HNCC	Pai	S.	USA	15,5
	• Personalized patient counseling	Dalianis	T.	Sweden	15,5
	• Discussion				25

17:00 - 18:15	H&N III - Decision-making in management of oropharyngeal cancers (OPC)	Auditorium 2			
	Chairs : T. Dalianis - R. Brakenhoff				
	• Treatment				
	- Non surgical	Lefebvre	J.L.	France	11
	- Surgical - robotic surgery	Fakhry	C.	USA	11
	• Radiosensitivity of HPV positive tumors	Lacau St Guily Mirghani	J. H.	France France	11
	• Prognosis & impact of HPV status in recurrent/metastatic OPC	Licitra	L.	Italy	11
	• Ongoing trials	Mehanna	H.	UK	11
	• Decision-making in head and neck cancers	Pai	S.	USA	11
	• Discussion				9

18:15 - 19:15	H&N IV - controversies and key questions	Auditorium 2			
	Chairs : J.L. Lefebvre - H. Mehanna- J. Lacau St Guily - F. Esteban - B. Burtness				
	• Debate				

8:00 - 9:30	SS 3 - FIGO session - Cervical cancer prevention in low-resource countries	Madrid			
	Chairs : L. Cabero-Roura				
	• Worldwide epidemiology of cervical cancer: prevalence, incidence, mortality. Rates and tendencies.	De Sanjosé	S.	Spain	16
	• Reality of HPV vaccination in under developed countries	LaMontagne	S.	USA	16
	• Cervical cancer in Africa: an epidemic in waiting?	Fiander	A.	UK	16
	• Effect of VIA screening by Primary Health workers: randomized controlled study in Mumbai, India	Shastri	S.	India	16
	• FIGO educational program	Bosch	X.	Spain	16
	• Discussion				10

9:30 - 11:30	SS 4 - Italian Session (in English) (to the memory of M. Sideri[†])	Madrid			
	Chairs : M. Sideri[†] - G. Ronco - M.-T. Sandri				
	• Overview and update on NTCC trial	Ronco	G.	Italy	12
	• Management of HPV+ women: results of research trials	Carozzi	F.	Italy	12
	• Update on the implementation of HPV primary screening in Italy	Giorgio-Rossi	P.	Italy	12
	• Performance of commercially available HPV tests (from studies to clinical practice)	Sandri	M.T.	Italy	12
	• Population-based frequency assessment of HPV-induced lesions in patients with borderline Pap tests in the Emilia Romagna region - the Pater study.	Costa	S.	Italy	12
	• Value of RLU in the management of ASC-US pap	Origoni	M.	Italy	12
	• Colposcopy in cytology negative HPV positive women	Preti	M.	Italy	12
	• CINtecplus to triage cytology negative HR positive women	Cristoforoni	P.	Italy	12
	• HPV vaccination in Italy, an update	Mariani	L.	Italy	12
	• Discussion				10

8:30 - 10:00	CS 5 - Clinical decision-making for cervical diseases	Bruselas			
	Chairs : A. Kaufmann- J.P. Bogers				
	• Pathognomonic signs guiding biopsy and therapy decision	Schneider	A.	Germany	13
	• It is the time to change the consensus about CIN 2-3 LLETZ treatment during the first trimester?	Siegler	E.	Israel	13
	• Managing 21-24 y women with CIN	Moscicki	A.B.	USA	13
	• Role of biomarkers in the management of high grade CIN	Wentzensen	N.	USA	13
	• Non-invasive treatment options for CIN	Hillemanns	P.	Germany	13
	• Risk factors for cervical cancer at colposcopy	Pretorius	R.	USA	13
	• Discussion				10

10:00 -	SS 5 - Spanish Session (in English)	Bruselas			
11:30	Chairs : R. Garrido - F. Martín-Torres				
	• Accreditation in colposcopy: The AEPCC's program	Dexeus	S.		16
	• The per-operative sample of HPV as a marker of risk of relapse or second lesion	del Pino	M.		16
	• Invasive cervical cancer quality control in Spain	Castillo	M.		16
		Ibáñez	R.		16
	• Robotic surgery in invasive cervical cancer	Ponce	J.		16
	• Discussion				10

8:30 -	SS 6 - Health economical modelling for HPV-induced cervical cancer prevention	Paris E Room			
10:15	Chairs : M. Brisson - H. Berkhof				
	• Optimal screening strategies in the era of vaccination in terms of cost-effectiveness - Australia	Canfell	K	Australia	15,5
	• Optimal screening strategies in the era of vaccination in terms of cost-effectiveness - The Netherlands	Berkhof	H.	Netherlands	15,5
	• Optimal number of HPV vaccine doses in terms of cost-effectiveness	Brisson	M.	Canada	15,5
	• Optimal HPV vaccine in terms of cost-effectiveness (bivalent, quadrivalent, nonavalent)	Jit	M.	UK	15,5
	• Comparing impact of different vaccination strategies (girls-only, girls & boys, and older women catch-up)	Baussano	I.	France	15,5
	• Investigating the impact of HPV vaccine on the cost-effectiveness of cervical screening in Denmark	Sopina	E.	Denmark	15,5
	• Discussion				10

10:15 -	SS 7 - Screening strategies at the extremes	Paris E Room			
11:30	Chairs : M. Elfström, P. Sasieni				
	• Cervical cancer risk in women <30y & >65y	Stoler	M.	USA	16
	• Screening of women <30y	Kinney	W.	USA	16
	• Screening of older women >65y	Sasieni	P.	UK	16
	• Management of ASCUS/LSIL women under 30	Elfström	M.	Sweden	16
	• Discussion				11

14:45 -	MSS 7 - New insights in cervical cancer control	Auditorium 3			
16:30	Chairs : J. Paavonen - S. Garland				
	• Community randomized HPV vaccination trial of the best vaccination strategy	Lehtinen	M.	Finland	25
	• The efficacy rates against CIN3 obtained by the quadrivalent and the bivalent vaccine Phase III trials were not identical-Why?	Paavonen	J.	Finland	15
	• Screening approaches for vaccinated population: Compass trial	Canfell	K.	Australia	15
	• How to integrate HPV vaccination programs and organized screening programs	Nieminen	P.	Finland	15
	• Addressing an unmet medical need using a 9-valent virus-like particle (VLP)-based HPV vaccine	Saah	A.	USA	15
	• Discussion				5

17:00 -	MSS 8 - Potential impact of the quadrivalent, bivalent and nonavalent HPV vaccines, and alternative HPV vaccination strategies	Auditorium 3			
18:15	Chairs : M. Brisson - M. Jit				
	• Impact of cross-protection on overall vaccination effectiveness against HPV-related diseases	Berkhof	H.	Netherlands	11
	• Alternative dosing schedules, WHO perspective	Henao-Restrepo	A.M.	Switzerland	11
	• Effectiveness and cost-effectiveness of the candidate nonavalent vaccine	Brisson	M.	Canada	11
	• Age-specific sexual activity patterns and HPV infection control	Baussano	I.	France	11
	• Effectiveness and cost-effectiveness of vaccinating Men-who-Have-Sex-with-Men	Jit	M.	UK	11
	• Impact of the nonavalent vaccine on cervical screening paradigms	Canfell	K.	Australia	11
	• Discussion				9

14:45 - 16:45	SS 8 - Cancers associated with HPV: the current picture	Madrid			
	Chairs : S. De Sanjosé - K. Syrjänen				
	• Introduction: overall picture and gaps	De Sanjosé	S.	Spain	12
	• Methodological issues	Franco	E.	Canada	12
	• Cervix - vagina - vulva and penis	De Sanjosé	S.	Spain	12
	• Anus	Fairley	C.	Australia	12
	• Head & neck	Mehanna	H.	UK	12
	• HPV persistence/p53 overexpression and treatment outcome post-endoscopic ablation of Barrett's esophagus	Rajendra	S.	Australia	12
	• Skin	Smola	S.	Germany	12
	• Other cancers	Syrjänen	K.	Finland	12
	• Ecology of high-risk human papillomavirus (HR-HPV) infections in heterosexual men (MSW), studied using expressed prostate secretions (EPS) versus anogenital samples	Eklund	C.	Sweden	12
	• Discussion				10

17:00 - 18:15	SS 9 - Self-sampling at the edge of becoming routines	Madrid			
	Chairs : M. Arbyn - N. Wentzensen				
	• Accuracy of HPV testing using self-collected vaginal specimen: an updated meta-analysis	Arbyn	M.	Belgium	13
	• Coverage increase by offering self-sampling kits to non-participating women	Verdoodt	F.	Belgium	13
	• How to triage women being hrHPV-positive on a self-sample	Verhoef	V.	Netherlands	13
	• HPV detection from urine- an alternative for self-sampling	Wentzensen	N.	USA	13
	• Can self-sampling become the main strategy in an HPV-based cervical cancer screening programme?	Heideman	D.	Netherlands	13
	• Discussion				10

14:45 - 16:30	SS 10 - Recent advances on HPV latency	Bruselas			
	Chairs : P. Gravitt				
	• ROPV models of latency and immunosuppression	Doorbar	J.	UK	15
	• Canine models of latency and role of vaccine in suppressing reactivation	Stanley	M.	UK	15
	• HPV latency in RRP: immune control and clinical implications	Steinberg	B.	USA	15
	• Evidence for latency in HIV-infected women	Gravitt	P.	USA	15
	• HPV load fluctuations and duration of detectable episodes vs. duration of infection in adolescents	Brown	D.	USA	15
	• HPV latency in menopausal women	Rositch	A.	USA	15
	• Discussion				15

17:00 -	SS 11 - New insights in immunology	Bruselas			
18:15	Chairs : S. van der Burg - A.B. Moscicki				
	• HPV immunology, genital vs oral	van der Burg	S.	Netherlands	13
	• Immunology of regression vs persistence	Moscicki	A.B.	USA	13
	• Immune responses to HPV prophylactic vaccines	Einstein	M.	USA	13
	• Novel approaches for therapeutic vaccination of HPV-associated neoplasia	Reuschenbach	M.	Germany	13
	• The role of natural immune control in the effectiveness of non-immune treatment	Kaufmann	A.	Germany	13
	• Discussion				10

18:15 -	SS 12 - The biology of HPV: what's new?	Bruselas			
19:30	Chairs : J. Doorbar - S. Smola				
	• HPV epithelial tropisms and the site-specific development of neoplasia	Doorbar	J.	UK	13
	• Epithelial target cell and the development of cervical disease; current thinking & observations	Reich	O.	Austria	13
	• Polymorphisms of the human leukocyte antigen DRB1 and DQB1 genes and HPV infection in the Ludwig-McGill study	Rodriguez	AM	Canada	13
	• HR + LR protein function in Alpha HPV infections and carcinogenesis	Banks	L.	Italy	13
	• Viral gene action during HPV infection - immune evasion strategies + persistence	Smola	S.	Germany	13
	• Discussion				10

14:45 -	CS 6 - HPV infection: the state of the art	Paris E Room			
16:30	Chairs : M. Goodman - E. Franco				
	• Men and women epidemiology - genital vs anal & oral	Giuliano	A.	USA	15,5
	• Immunological factors which may be common or different at oral, anal or genital sites of infection	Stern	P.	UK	15,5
	• HPV infection in children	Syrjänen	S.	Finland	15,5
	• Current knowledge on transmission	Goodman	M.	USA	15,5
	• The environment of HPV	Moscicki	A.B.	USA	15,5
	• Prevention: vaccination vs education	Romanowski	B.	Canada	15,5
	• Discussion				12

17:00 -	CS 7 - Anogenital HPV infection in men	Paris E Room			
18:15	Chairs : B. Lu - J. Palefsky				
	• Anal cancer screening - The role of digital rectal exam	Nyitray	A.	USA	11
	• The utility of HR anoscopy in the management of AIN	Bower	M.	UK	11
	• Epidemiology of anal HPV infection, transmission and natural history	Lu	B.	USA	11
	• Management of genital warts: updated guidelines	Steben	M.	Canada	11
	• Performance of anal Aptima HPV testing alone and with anal cytology for detection of anal high-grade squamous intraepithelial lesions	Palefsky	J.	USA	11
	• Genital high-risk human papillomavirus (HPV) infection among men in Denmark: prevalence and risk factors	Hebnes	J.	Denmark	11
	• Discussion				9

Saturday, Feb. 7

8:30 - 10:00	MSS9 - HPV vaccines: unexpected findings	Auditorium 3			
	Chairs : E. Joura - B. Romanowski				
	• L2-based HPV second generation vaccines (RG1-VLP)	Schellenbacher	C.	Austria	13
	• Attribution of vaccine types in mixed infection	Joura	E.	Austria	13
	• HPV vaccination in immunosuppressed	Moscicki	A.B.	USA	13
	• Utility of fewer doses - effectiveness	Romanowski	B.	Canada	13
	• Impact of HPV 16-18 vaccination on genital warts	Soldan	K.	UK	13
	• Cross-neutralising antibodies in the cross-protection against 16/18 by bivalent & quadrivalent vaccines	Paavonen	J.	Finland	13
	• Discussion				12

10:00 - 11:30	MSS 10 - Novel approaches of HPV and non HPV-based cervical cancer screening	Auditorium 3			
	Chairs : P. Snijders - K. Cuschieri				
	• Biomarker tests	von Knebel Doeberitz	M.	Germany	13
	• Methylation	Snijders	P.	Netherlands	13
	• Genotyping	Cuzick	J.	UK	13
	• mRNA	Cuschieri	K.	UK	13
	• Self-sampling	Heideman	D.	Netherlands	13
	• Novel approaches of HPV and non-HPV-based cervical cancer screening in developing countries	Lorincz	A.	UK	13
	• Discussion				12

11:30 - 13:00	SS 13 - Basic molecular techniques and quality control of HPV testing	Auditorium 3			
	Chairs : M. Poljak - F. Carozzi				
	• Quality control of HPV testing in cervical cancer screening: from the patient sample to the communication of the results	Cubie	H.	UK	11,5
	• Commercially available HPV tests, global overview and future challenges	Poljak	M.	Slovenia	11,5
	• Cervical cancer screening of the vaccinated cohorts	Arbyn	M.	Belgium	11,5
	• Clinically oriented external quality assurance programmes for HPV diagnostic tests: urgent need	Carozzi	F.	Italy	11,5
	• Internal quality control requirements and external quality assurance programs for commercial and in-house HPV genotyping tests: current status	Eklund	C.	Sweden	11,5
	• Novel HPV types beyond HPV-150: an overview	Dillner	J.	Sweden	11,5
	• Global genomic diversity of HPV 6 and 11	Jelen	M.	Slovenia	11,5
	• Discussion				9

8:15 -	OC 12 - Screening	Auditorium 2			
10:00	Chairs : B. Andrae - E. Lynge				
	• Liquid based cytology (ThinPrep) and computer assistance compared to conventional cytology; seven years' experience in 310 203 cases	Xhaja	A.	Germany	8
	• Normal smears and specimens with benign cellular changes: are they really equivalent? Data from 95 934 cases	Baldauf	J.J.	France	8
	• Benefit of cervical screening in young women - a matter of adherence to the recommended screening interval	Sparen	P.	Sweden	8
	• Age at first smear and cervical cancer risk: recent UK incidence and mortality trends	Gilham	C.	UK	8
	• Cervical cancer incidence after a negative smear: comparing SurePath and ThinPrep with conventional cytology	Rozemeijer	K.	Netherlands	8
	• Hysterectomy and its impact on the calculated incidence of cervical cancer and screening coverage rate in Denmark	Lynge	E.	Denmark	8
	• Evaluation of three strategies to increase cervical cancer screening coverage among women age 30 to 70 years old. CRICERVA	De Sanjosé	S.	Spain	8
	• Impact of overscreening, data from a French organized programme	Fender	M.	France	8
	• Cervical cancer prevented by screening: long-term incidence trends by morphology and region in Norway	Lönnerberg	S.	Norway	8
	• Estimating the contribution from unspecified uterine cancer to cervical cancer mortality	Andrae	B.	Sweden	8
	• The impact of cervical cancer screening on preterm birth: a decision analysis	Naber	S.	Netherlands	8
	• Effect of HR-HPV immunisation on the performance of cervical cytology	Palmer	T.	UK	8
	• Characteristics of GPs who do not engage in cervical cancer screening in France	Poncet	L.	France	8

10:00 -	OC 13 - HPV Screening	Auditorium 2			
12:00	Chairs : M. Rebolj - F. Carozzi				
	• Misleading round 1 results in HPV screening studies due to high rate of previously undiagnosed CIN3	Peto	J.	UK	7,5
	• Complete age specific round 1 results from the Canadian population-based screening trial: HPV focal	Ogilvie	G.	Canada	7,5
	• Human papillomavirus assays and cytology in primary cervical screening of women below age 30 years	Bonde	J.	Denmark	7,5
	• Referral population studies in evaluation of HPV assays for primary screening	Rebolj	M.	Denmark	7,5
	• The long-term prognostic value of HPV testing and Pap cytology to detect cervical neoplasia in the Canadian cervical cancer screening trial (CCCaST)	Isidean	S.	Canada	7,5
	• Evaluating the potential introduction of primary HPV DNA screening in England	Bains	I.	UK	7,5
	• HPV testing with cytological triage versus conventional cytology in an organized cervical cancer screening program	Veijalainen	O.	Finland	7,5
	• Performance of HPV DNA testing with individual HPV 16/18 genotyping for primary cervical cancer screening and triage, compared to cytology	Agorastos	T.	Greece	7,5
	• Clinical characteristics of samples where cobas, HC2, Aptima, and CLART HPV assays return different test results	Rygaard	C.	Denmark	7,5
	• The added value of rescreening cytology normal samples with positive HPV mRNA test for the detection of CIN2+ in primary screening	Skjeldestad	F.	Norway	7,5
	• Exploring the value of a rapid, on demand test for HPV as part of cervical cancer screening pathways	Adams	E.	UK	7,5
	• Start-HPV French pilot primary screening program for cervical cancer: participation results	Dalstein	V.	France	7,5
	• Introducing careHPV into a public sector screening program in El Salvador	Cremer	M.	USA	7,5
	• Randomized implementation of HPV-test in primary screening in the Norwegian cervical cancer screening program	Andreassen	T.	Norway	7,5
	• Cervical cancer screening program based on cytology and HPV test: positive predictive value	Tamames	S.	Spain	7,5
	• HPV screening pivotal study in the Netherlands	Bogers	J.P.	Belgium	7,5

12:00 -	OC 14 - Self-sampling	Auditorium 2			
13:15	Chairs : D. Heideman - J. Bonde				
	• HPV prevalence findings in the Danish HPV self-sampling implementation compared to routine screening	Pedersen	H.	Denmark	9
	• Comparative evaluation of two vaginal self-sampling devices for the detection of human papillomavirus infections	Jentschke	M.	Germany	9
	• Good agreement of HPV detection between self-collected dry samples and physician-collected specimens in China	Chen	K.	Germany	9
	• HPV-based self-sampling implementation with an opt-in strategy to improve cervical screening coverage	Lam	J.	Denmark	9
	• Clinical validation of self HPV testing in routine screening in Scotland	Stanczuk	G.	UK	9
	• ACCESSING*: screening by self-sampling and low cost Arbor Vita E6 oncoprotein test can detect dysplasia in high risk women	Effah	K.	Ghana	9
	• Feasibility of self-collection and dry specimen storage for HPV mRNA testing to detect cervical lesions in high risk women	Manguro	G.	Kenya	9
	• Self-collected vs. provider-collected sampling for HPV DNA testing in a population-based cervical cancer prevention program in rural El Salvador	Felix	J.C.	USA	9

8:00 -	SS 14 - CoheaHr	Madrid			
10:00	Chairs : C. Meijer - M. Elfström				
	• Overview of CoheaHr. Self-sampling for primary HPV screening	Berkhof	H.	Netherlands	14
	• Comparative effectiveness research in optimization of cervical cancer control	Dillner	J.	Sweden	14
	• HPV clearance rates: impact on cervical cancer control strategies	Ronco	G.	Italy	14
	• HPV transmission modelling in optimizing preventive strategies	Baussano	I.	France	14
	• Vaccination of mid-adult women	Bosch	X.	Spain	14
	• Efficacy of HPV vaccines	Arbyn	M.	Belgium	14
	• Effect of vaccination strategies on screening	Veldhuijzen	N.	Netherlands	14
	• Integration of vaccination and screening	Lehtinen	M.	Finland	14
	• Discussion				8

10:00 - 11:30	SS 15 - Prevention of cervical cancer in Central and Eastern Europe and Central Asia	Madrid			
	Chairs : M. Poljak				
	• Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia	Bray	F.	France	16
	• Cervical cancer screening practices and current status of vaccination implementation in the Russian Federation	Rogovskaya	S.	Russia	16
	• Cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe	Seme	K.	Slovenia	16
	• Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia	Berkhof	H.	Netherlands	16
	• Recommendations for cervical cancer prevention in Central and Eastern Europe and Central Asia	Poljak	M.	Slovenia	16
	• Discussion				10

11:30 - 13:00	SS 16 - HPV infection, cervical cancer prevention in low income countries	Madrid			
	Chairs : R. Sankaranarayanan				
	• Cervical cancer prevention initiatives in China: Care HPV	Qiao	Y. L.	China	13
	• Updated results from the Indian study of less than 3 doses of HPV vaccination	Sankaranarayanan	R.	France	13
	• Cervical cancer prevention in HIV infected women	Smith	J.	USA	13
	• Infection with <i>C. trachomatis</i> increases high-risk human papillomavirus infection duration among female sex workers in Kenya	Vielot	N.	USA	13
	• Developing a sustainable programme of cervical screening by 'see and treat' in rural Malawi	Cubie	H.	UK	13
	• Risk factors for HIV positivity according to HPV status among Tanzanian women	Faber	M.	Denmark	13
	• Discussion				12

8:30 - 10:00	OC 15 - Anal neoplasia	Bruselas			
	Chairs : J. Palefsky - A. Nyitray				
	• Diagnostic value of anal cytology, HPV testing and high resolution anoscopy (HRA) in screening for anal intraepithelial neoplasia (AIN) in HIV positive individuals	Grover	D.	UK	15
	• Persistence, incidence, and clearance of anal HPV among HIV-negative men having sex with men and men having sex with women and men	Nyitray	A.	USA	15
	• The effect of HIV infection on anal high-risk HPV incidence and clearance among MSM	Mooij	S.	Netherlands	15
	• Correlates of higher burden of anal high-grade squamous intraepithelial lesions (HSIL) in the study for the prevention of anal cancer (SPANC)	Templeton	D.	Australia	15
	• Stratifying risk of development of anal cancer - a proposed clinical algorithm	Poynten	M.	Australia	15
	• Anal cancer screening in HIV positive Czech MSM	Kaspirkova	J.	Czech Republic	15

10:00 - 11:30	OC 16 - Vulvar, vaginal & other neoplasia	Bruselas			
	Chairs : A. Tristram - F. Borruto				
	• Sexual activity and function in patients with preinvasive and invasive vulvar lesions after completed treatment	Grimm	D.	Germany	15
	• Role of vulvar cytology vs colposcopy in women with chronic vulvovaginal complaints and future role of HPV PCR as a primary screening modality	Wadhwa	S.	India	15
	• Randomized trial of treatment and follow-up of vaginal intraepithelial neoplasia	Tainio	K.	Finland	15
	• Risk factors and outcomes of women with vaginal intraepithelial neoplasia grade 2 and 3 (VaIN 2/3) - an eleven-year experience	Seet	M.J.	Singapore	15
	• Trends in mortality of human papillomavirus-related cancers in 1975-2012, from the Kanagawa cancer registry, Japan	Motoki	Y.	Japan	15
	• HLA class II antigen expression in cervical intraepithelial neoplasia and invasive cancer	Sauer	M.	Germany	15

11:30 -	OC 17 - Molecular markers biology & immunology	Bruselas			
13:00	Chairs : M. von Knebel Doeberitz - M. Safaeian				
	• Methylation of human papillomavirus 16 L1 gene in cervical intraepithelial neoplasia and cancer	Gutierrez	A.	Germany	8
	• Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3	Schuuring	E.	Netherlands	8
	• HPV OncoTect Quantitative E6, E7 mRNA as a Single Test Alternative to HPV 16, 18 and PAP Reflex Following Primary HPV DNA Screening	King	D.	USA	8
	• Genome-wide methylome analysis discovers novel methylation markers for both cervical adenocarcinomas and squamous cell carcinomas	Wisman	G.	Netherlands	8
	• Comparison of manual processing for p16/ki-67 dual stain	Ikenberg	H.	Germany	8
	• Established and novel protein biomarkers for early detection of cervical cancer cells	Jansen-Dürr	P.	Austria	8
	• Epigenetic control of human papillomavirus late gene expression	Von Knebel Doeberitz	M.	Germany	8
	• Identification of novel key modules regulating cell cycle and apoptosis in cervical carcinoma	Pappa	K.	Greece	8
	• The epigenetic drug 5-AZA-2'-deoxycytidine downregulates the viral oncogenes E6 & E7 AND reduces proliferation in HPV associated cancers	Stich	M.	Germany	8
	• Cofilin-1 and Cathepsin-D are putative early cervical cancer biomarkers	Anagnou	K.	Greece	8
	• Secretome map study of normal and malignant cervical cell lines	Kontostathi	G.	Greece	8

POSTERS

Epidemiology

P1-1	• Prevalence of HPV in a Portuguese population centre Lisbon	Cochicho	D.	Portugal	
P1-2	• Prevalence of intraepithelial lesions of the lower genital tract in patients <24 years	Tatti	S.	Argentina	
P1-3	• Detection of beta and gamma human papillomaviruses in anal swabs of HIV-infected and uninfected men who have sex with men	Dona	M.G.	Italy	
P1-4	• Mother-to-infant transmission of high-risk human papillomavirus	Borruto	F.	Monaco	
P1-5	• Pattern of high-risk HPV viral load after quadrivalent HPV vaccination in patients treated by conization	Paek	J.	South Korea	
P1-6	• Genotype distribution of human papillomavirus in men from Salvador, Bahia, Brazil	Serravalle	K.	Brazil	
P1-7	• HPV types present in external genital warts in the Argentinean population	Fleider	L.	Argentina	
P1-8	• Distribution of cervical lesions in São Tomé e Príncipe Democratic Republic - a middle Africa Country	Gonçalves	L.	Portugal	
P1-9	• Performance of cobas 4800 HPV testing and genotype - specific distribution in opportunistic cervical cancer screening	Mateos	M.L.	Spain	
P1-10	• Natural history of cervical HPV infections in different groups of high risk women enrolled in the VALHIDATE study	Orlando	G.	Italy	
P1-11	• HPV genotypes in intraanal samples of immunocompetent women and clinical and liquid-based cytology findings	Eleutério	J.	Brazil	
P1-12	• High prevalence of human papillomavirus (HPV) in vulvar and vaginal carcinomas from Brazil	Saddi	V.	Brazil	
P1-13	• High grade squamous intraepithelial lesion in an adolescent: a case study	Andrade	V.	Brazil	
P1-14	• Is there a clinical profile for patients with persistent HPV infection after conization ?	Olalla Jimenez	M.	Spain	
P1-15	• Prevalence of chlamydia trachomatis infection on a cohort of selected asymptomatic young women in Milan, Italy	Bianchi	S.	Italy	
P1-16	• Sexual behavior and HPV infection in adolescents and young women	Ribeiro	A.	Brazil	
P1-17	• Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in Martinique (French West Indies)	Cesaire	R.	France	
P1-18	• Human papillomavirus genotypes in São Tomé e Príncipe Democratic Republic - a middle Africa Country	Nobre	R.	Portugal	
P1-19	• Role of quantitative viral load and physical status of Human papilloma virus (HPV) type 16 for prognosis of effectiveness of cervical cancer treatment	Mkrtchyan	L.	Russia	

Vaccine

P2-1	• Evaluating the early impact of quadrivalent HPV vaccine introduction on genital warts in Belgium	Dominiak-Felden	G.	Belgium	
P2-2	• Assessing type-replacement following HPV vaccination	Palmroth	J.	Finland	
P2-3	• Cancer registry follow-up of HPV vaccination trial cohorts and unvaccinated cohorts	Paavonen	J.	Finland	
P2-4	• Cost-effectiveness of HPV vaccination in developing countries	Natunen	K.	Finland	
P2-5	• Projecting the potential public health impact of a 9-valent HPV vaccine in the Czech Republic	Pillsbury	M.	USA	
P2-6	• Baseline characteristics of a randomized screening trial of HPV vaccinated women	Nieminen	P.	Finland	
P2-7	• Prevalence of HPV DNA in adolescent men vaccinated with the HPV 16/18 vaccine	Petäjä	T.	Finland	
P2-8	• Prevalence of genital HPV infection in women aged 18-29, in the post vaccination period, Quebec, Canada	Goggin	P.	Canada	
P2-9	• Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France	Riethmüller	D.	France	
P2-10	• Projecting the potential public health impact of a vaccination programme with a nine-valent HPV vaccine in Norway	Adam	M.	France	
P2-11	• Projecting the potential public health impact of a 9-valent HPV vaccine in Hungary	Pillsbury	M.	USA	
P2-12	• Correlation between local and systemic IgG and IgA responses against HPV-16/18 VLP during HPV vaccination	Giraldo	P.	Brazil	
P2-13	• Provider insight into strategies to increase HPV vaccine uptake: a multi-site study	Islam	J. Y.	USA	
P2-14	• Performance of a trial organization in the conduct of a large cluster-randomized trial	Lehtinen	M.	Finland	

HPV testing

P3-1	• Modified pre-processing method for SurePath liquid-based cytology: assessing impact on the performance of the realtime high-risk HPV assay	Sargent	A.	UK	
P3-2	• Comparison of HPV direct flow chip system with Hybrid Capture II method for detection of human papillomavirus in women with previous abnormal Pap smears	Olmo	A.	Spain	
P3-3	• Primary HPV test in cervical cancer screening in Latin (Italy)	Della Rocca	C.	Italy	
P3-4	• Comparison of Xpert® HPV assay versus Aptima® HPV assay	Henley	D.	USA	
P3-5	• Comparison between direct sequencing and direct flow chip for human papillomavirus (HPV) genotyping, in formalin-fixed paraffin-embedded (FFPE) biopsies	Garcia	J.A.	Spain	
P3-6	• Comparison between a realtime-PCR, DNA-based HPV test and the HPV APTIMA	Helenius	G.	Sweden	
P3-7	• Improving laboratory efficiency by automation of pre-analytic processing of ThinPrep specimens for realtime high risk HPV testing	Venturoli	S.	Italy	
P3-8	• Cervical cytology specimen stability in SurePath preservative and analytical sensitivity for HPV testing with the cobas® and Hybrid Capture 2® tests	Tardif	K.	USA	
P3-9	• Quality assurance of HPV testing within the NHSCSP	Hesketh	L.	UK	
P3-10	• HPV detection and typing by molecular diagnostic Microarray	Cavalar	M.	Germany	
P3-11	• Triple negative breast cancers (TNBC) and markers of HPV involvement	Bews-Hair	M.	UK	
P3-12	• Statistical study of HPV genotypes in Barbastro area	Comes García	M.D.	Spain	
P3-13	• Comparison of two HPV genotyping methods: HPV direct flow chip and GenoFlow HPV array kit	Marques	L.	Spain	
P3-14	• Comparison of FLOQSwabs for cervico-vaginal self-collection to gynecologist collected cervical specimens for the detection of HPV-DNA with Anyplex™II HPV28 assay.	Castriciano	S.	Italy	

HPV testing (cont'd)

P3-15	• Quality of life of persistently HPV DNA screen-positive women	Eriksson	T.	Finland	
P3-16	• Organization of in-depth examination of the Rostov region female population with the aim of cervical disease detection at the facilities of regional clinical diagnostic center	Kholodnaya	T.	Russia	
P3-17	• Biochemical investigations of human papillomavirus infected cervical fluids	Kim	Y.H.	South Korea	
P3-18	• Persistence of HPV after conization in a referral hospital in Spain	Pérez Rodríguez	S.	Spain	
P3-19	• Comparison between HPV OncoTect and nucliSENS EasyQ assay and its potential role in detecting preneoplastic lesions of the cervix	Rongioletti	M.	Italy	
P3-20	• The 16, 18 and 45 HPV infection triage in primary hr-HPV test screening program	Di Cristofano	C.	Italy	
P3-21	• Clinical validation of the Anyplex II HPV HR detection for the cervical cancer screening in Korea	Kim	S.Y.	South Korea	
P3-22	• Improved method for Human Papillomavirus detection and characterization without DNA extraction, using a low density microarray technology, CLART® HPV-4.	Moraga	A.	Spain	
P3-23	• Comparative analysis of cervical cytology and HPV genotyping by 3 different methods in routine diagnostic setting	Padalko	E.	Belgium	
P3-24	• Detection of high-risk HPV (hrHPV) genotypes among the Ecuadorian female population with cobas 4800	Zambrano	H.	Ecuador	
P3-25	• GeneXpert® HPV assay evaluation in a LSIL setting	Sousa	C.	Portugal	

Molecular markers

P4-1	• Using acute oncology to drive translational science: identifying potential biomarkers to overcome resistance mechanisms of ovarian cancer	Kwok	J.	UK	
P4-2	• Type-specific HPV prevalence in women at high risk of invasive cervical disease: data from the baseline of the Italian VALHIDATE study	Tanzi	E.	Italy	
P4-3	• Structural and level oncogenicity correlation between human papillomavirus variants E7	Tamarozzi	E.	Brazil	
P4-4	• Overexpression of HPV E6/E7 mRNA: a marker for high-grade squamous intraepithelial lesions progression in Puerto Rican population	Melendez	K.	Puerto Rico	
P4-5	• Human papillomavirus E6/E7 mRNA as cervical cancer biomarker	Basaras	M.	Spain	
P4-6	• mRNA expression of genes KI67, p16, PGR and BCL2 as markers of increased risk of neoplastic transformation with HPV-associated cervical disease	Nazarova	N.	Russia	
P4-7	• Proteomic map study of cervical cancer cell lines	Lygirou	V.	Greece	

Screening

P5-1	• Optimal age for the onset of HPV-based primary cervical cancer screening using the cobas® HPV test	Chatzistamatiou	K.	Greece	
P5-2	• High risk human papillomavirus population screening and intratypic variants detection in northern Spain	Cisterna	R.	Spain	
P5-3	• In silico modeling of human papillomavirus type 16 (HPV16) E6 protein	Giuliatti	S.	Brazil	
P5-4	• Restriction of cervical cancer in Latvia: opportunities and challenges	Jermakova	I.	Latvia	
P5-5	• Cancer screening in low resource setting	Kirubamani	H.	India	
P5-6	• Modeling to improve: coverage and participation rate in an organized cervical cancer screening program	Tamames	Sonia	Spain	
P5-7	• Cervical cancer screening: Albania's dilemmas and preliminary results	Shundi	L.	Albania	
P5-8	• Cost-effectiveness of HPV DNA versus HPV mRNA testing under current United States guidelines for cervical cancer screening	Smith	J.	USA	
P5-9	• Secondary prevention of cervix cancer in the Madrid region: a proposal for a change	Hernandez-Aguado	J.	Spain	
P5-10	• p16/Ki-67 dual-stain cytology in cervical cancer screening: future is now? Our own experience in a first level hospital	Zambruno	A.	Spain	

Diagnosis methods

P6-1	• Raman microspectroscopy for cytological screening of cervical cancer	Ramos	I.	Ireland	
P6-2	• Application of 2-tiered nomenclature for cervical intraepithelial neoplasia in clinic	Zhao	Y.	China	
P6-3	• Anoscopy could be beneficial for women with external genital condyloma ?	Aynaud	O.	France	

Colposcopy & management

P7-1	• Colposcopic findings in cervical dysplasia	Baasland	I.	Norway	
P7-2	• Investigation of the biochemical signature associated with HPV E7 oncogene expression using Raman spectroscopy	Kearney	P.	Ireland	
P7-3	• A single colposcopist can improve detection of invasive cervical cancer in women with negative cytology in Brazil	Resende	L.	Brazil	
P7-4	Dynamic spectral imaging for triage of low grades	Naik	R.	UK	
P7-5	• New technology for cervical cancer screening and HPV testing based on Raman spectroscopy	Traynor	D.	Ireland	
P7-6	• Tumor-cervical tuberculosis: report of a case	Gassama	O.	Senegal	
P7-7	• Diagnostic and therapeutic management of cervical intraepithelial neoplasia grade 2 (CIN2)	Garutti	P.	Italy	

Cervical cancer

P8-1	• Differences in relapsed pattern between radical hysterectomy and radical trachelectomy in the management of early cervical cancer	Choi	S.Y.	South Korea	
P8-2	• Cervical cancer staging: an imaging review	McIntosh	L.	USA	
P8-3	• Reduced glycosylation levels of serum anti-HPV type 16 E7 immunoglobulin are critical markers indicating cervical carcinogenesis	Kim	S.C.	South Korea	
P8-4	• Comparative study of Robotic radical hysterectomy versus laparoscopic radical hysterectomy in cervical cancer	Kwon	S.H.	South Korea	

Head & Neck

P9-1	• Prevalence and expression of human papillomavirus in Greek patients with head and neck squamous cell carcinomas	Panotopoulou	E	Greece	
P9-2	• High-risk HPV-associated hypopharyngeal cancers occur frequently in the pyriform sinus	Park	J.O.	Japan	
P9-3	• 18F-FDG PET/CT and high-risk HPV in hypopharyngeal squamous carcinoma	Kim	S.Y.	Japan	
P9-4	• The burden of head & neck cancers in Iași, Romania	Ursu	R.	Romania	

Sexually transmitted diseases

P10-1	• Longterm prediction accuracy of HPV testing for cervical cancer prediction	Chen	H.C.	Taiwan	
P10-2	• Uncaria tomentosa and topical use in genital herpes in vulva: case report	Fedrizzi	E.	Brazil	
P10-3	• Placentitis cryptococcal pregnant patient HIV + associated with opportunistic comorbidities: case report	Silva	C.	Brazil	

Treatment & management

P11-1	• Early decrease in anogenital warts treatment when introducing a broad quadrivalent HPV vaccination program: a study from 3 Nordic countries	Olsen	D.	Norway	
P11-2	• Dynamin II as potential therapeutic target in cervical carcinoma	Lee	J.W.	South Korea	
P11-3	• $\alpha 2B$ -interferon and tilorone in the treatment of CIN with lesions of the vaginal fornix and walls	Lygyrda	N.	Ukraine	
P11-4	• Histological correlations in cases of ASCUS or ASC-H cytology and HPV cervical infection	Dinca	G.	Romania	
P11-5	• Frequency and characteristics of affected edges after conization	Jurado Navarrete	I.	Spain	
P11-6	• Successful treatment of a giant condyloma acuminatum of vulva	Mendes	S.	Portugal	

Health education

P12-1	• The affordable care act: the women who will be left behind	Ramondetta	L.	USA	
P12-2	• Psychosocial impact of genital warts and other HPV-related diseases in South Korea	Lee	T.-S.	South Korea	